



PRELIMINARY SCIENTIFIC PROGRAM (Subject to changes – as of February 11, 2024)

SATURDAY, MARCH 23, 2024

08:20-11:00	Amyotrophic lateral sclerosis/Motorneuron disease (ALS/MND)	HALL A
Chair:	TBA	
08:20-09:10	Human cell models are better than mouse models in therapy development for ALS/MND <i>Capsule: Given the limitations of currently available mouse models of ALS/MND and the lack of a mouse model for sporadic disease, human cellular models have key advantages in the evaluation of potential neuroprotective therapies.</i>	
08:20-08:30	Moderator: Amir Dori , Israel Introduction and Pre-Debate Voting	
08:30-08:45	Yes : Pam Shaw , UK	
08:45-09:00	No: Linda Greensmith , UK	
09:00-09:10	Discussion, Rebuttals and Post-Debate Voting	
09:10-10:00	ALS/MND treatments have to demonstrate efficacy on both prolonging survival and slowing disease progression <i>Capsule: In the absence of improved function, prolonged survival by a few months may not necessarily indicate attenuation of disease progression. Therefore, evidence for slowed disease progression is required</i>	
09:10-09:20	Moderator: Amir Dori , Israel Introduction and Pre-Debate Voting	
09:20-09:35	Yes: Albert Ludolph , Germany	
09:35-09:50	No: Osman Sinanovic , Bosnia and Herzegovina	
09:50-10:00	Discussion, Rebuttals and Post-Debate Voting	
10:00-11:00	The euphoria on personalized ALS/MND treatment with Antisense oligonucleotides (ASO) is premature <i>Capsule: Treatment with ASOs for specific genetic subtypes of ALS/MND has shown some promising results, but euphoria is premature given the rarity of these subtypes and the failure of some ASO approaches.</i>	
10:00-10:10	Moderator: Osman Sinanovic , Bosnia and Herzegovina Introduction and Pre-Debate Voting	
10:10-10:25	Yes: Pam Shaw , UK	
10:25-10:40	No: Giancarlo Logroscino , Italy	
10:40-11:00	Discussion, Rebuttals and Post-Debate Voting	

14:30- 16:10	Amyotrophic lateral sclerosis/ motorneuron disease (ALS/MND) 2	HALL A
Chair:	Ervin Jancic , Croatia	
14:30-15:20	Tracheostomy ventilation in ALS/MND should be offered to all patients	
	Capsule: Neuromuscular respiratory failure is the cause of death in most patients with ALS/MND. Invasive tracheostomy ventilation adds a burden of care while non-invasive respiratory support is readily available.	
14:30-14:40	Moderator: David Oliver , UK Introduction and Pre-Debate Voting	
14:40-14:55	Yes: Giancarlo Logroscino , Italy	
14:55-15:10	No: Albert Ludolph , Germany	
15:10-15:20	Discussion, Rebuttals and Post-Debate Voting	
15:20-16:10	gMG patients with highly active disease should be treated with innovative treatments earlier	
	Capsule :	
15:20-15:30	Moderator: TBA	
15:30-15:45	Yes: Celia Oreja-Guevara , Spain	
15:45-16:00	No: TBA	
16:00-16:10	Discussion, Rebuttals and Post-Debate Voting	
16:30-18:10	Neurodegenerative diseases	HALL A
Chair:	Johannes Attems , UK	
16:30-17:20	Will anti-tau drugs be useful in fighting tau-driven diseases?	
	<i>Capsule: Tauopathies are very common pathology changes in neurodegenerative diseases, particularly AD, in which the tau burden is composed of hyperphosphorylated tau proteins. The large number of individuals affected by tauopathies and the theory that this leads to neurodegeneration have led to a search for disease-modifying therapies targeting tau pathology. None has proven useful so far. Is the search worthwhile?</i>	
16:30-16:40	Moderator: Bogdan Popescu , Romania Introduction and Pre-Debate Voting	
16:40-16:55	Yes: Lea Grinberg , USA	
16:55-17:10	No : Jesse Cedarbaum , USA	
17:10-17:20	Discussion, Rebuttals and Post-Debate Voting	
17:20-18:10	Pathological changes in microglia were linked to pathology in different neurodegenerative diseases. Can we target microglia to develop a therapeutic approach?	
	<i>Capsule: Activation of microglia is considered a pathological hallmark in many neurodegenerative diseases. While microglia are essential for normal brain activity, impairment in their activity may exacerbate neuroinflammation and result in neuronal death. Should microglia be a target for therapeutic intervention to ameliorate disease pathology in neurodegenerative diseases?</i>	
17:20-17:30	Moderator: Jesse Cedarbaum , USA Introduction and Pre-Debate Voting	
17:30-17:45	Yes: Dan Frenkel , Israel	
17:45-18:00	No: Bogdan Popescu , Romania	
18:00-18:10	Discussion, Rebuttals and Post-Debate Voting	

